Morbidity of surgery after neoadjuvant chemotherapy including bevacizumab for advanced ovarian cancer

International Journal of Gynecological Cancer

Volumn 23, Issue 7, 2013, Pages 1326-1330

  Chéreau, Elisabeth ^a   Lambaudie, Eric ^a   Houvenaeghel, Gilles ^a  

^a INSTITUT PAOLI CALMETTES   (France)

Author keywords

Advanced ovarian cancer; Bevacizumab; Debulking surgery; Morbidity; Neoadjuvant chemotherapy

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; PACLITAXEL;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; ADVANCED OVARIAN CANCER; AGED; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CANCER ADJUVANT THERAPY; COMPUTER ASSISTED TOMOGRAPHY; CYSTIC LYMPHANGIOMA; CYTOREDUCTIVE SURGERY; DRUG SAFETY; FEMALE; FEVER; HUMAN; INTENSIVE CARE UNIT; INTESTINE FISTULA; LUNG EMBOLISM; LYMPHEDEMA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MORBIDITY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PLEURA EFFUSION; PNEUMOTHORAX; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; TREATMENT DURATION; URINARY TRACT INFECTION;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; MORBIDITY; NEOADJUVANT THERAPY; NEOPLASM STAGING; OVARIAN NEOPLASMS; OVARIECTOMY; PACLITAXEL; POSTOPERATIVE COMPLICATIONS; PROGNOSIS;

EID: 84884503883     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31829dc923     Document Type: Article

References (27)

1. Vergote I, Tropé CG, Amant F, et al. European Organization for Research and Treatment of CancerYGynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943-953.
2. Chi DS, Zivanovic O, Palayekar MJ, et al. A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma. Gynecol Oncol. 2009;112:6-10.
3. Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: A prospective study. Gynecol Oncol. 1998;69:103-108.
4. Chi DS, Zivanovic O, Levinson KL, et al. The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas. Gynecol Oncol. 2010;119:38-42.
5. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007;25:5180-5186.
6. Burger RA, Brady MF, Bookman MA, et al. Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473-2483.
7. Perren TJ, Swart AM, Pfisterer J, et al. ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484-2496.
8. Han ES, Monk BJ. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol Oncol. 2007;105:3-6.
9. Sugarbaker PH. Management of peritoneal-surface malignancy: The surgeon's role. Langenbecks Arch Surg. 1999;384:576-587.
10. Martin RC 2nd, Brennan MF, Jaques DP. Quality of complication reporting in the surgical literature. Ann Surg. 2002;235:803-813.
11. Alexandre J, Joly F, Lhommé C, et al. AVASTIN et autres thérapies ciblées. Recommandations de St Paul de Vence. 2012. http://www.arcagy.org/arcagy-organisation-et-recherche/index.php?id=1128.
12. Chéreau E, Ballester M, Lesieur B, et al. Complications of radical surgery for advanced ovarian cancer. Gynecol Obstet Fertil. 2011;39:21-27.
13. Richardson DL, Mariani A, Cliby WA. Risk factors for anastomotic leak after recto-sigmoid resection for ovarian cancer. Gynecol Oncol. 2006;103:667-672.
14. Tamussino KF, Lim PC, Webb MJ, et al. Gastrointestinal surgery in patients with ovarian cancer. Gynecol Oncol. 2001;80:79-84.
15. Houvenaeghel G, Gutowski M, Buttarelli M, et al. Modified posterior pelvic exenteration for ovarian cancer. Int J Gynecol Cancer. 2009;19:968-973.
16. Gillette-Cloven N, Burger RA, Monk BJ, et al. Bowel resection at the time of primary cytoreduction for epithelial ovarian cancer. J Am Coll Surg. 2001;193:626-632.
17. Gerestein CG, Damhuis RA, Burger CW, et al. Postoperative mortality after primary cytoreductive surgery for advanced stage epithelial ovarian cancer: A systematic review. Gynecol Oncol. 2009;114:523-527.
18. Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol. 2008;26:76-82.
19. Penson RT, Dizon DS, Cannistra SA, et al. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol. 2010;28:154-159.
20. Sehouli J, Papanikolaou G, Braicu EI, et al. Feasibility of surgery after systemic treatment with the humanized recombinant antibody bevacizumab in heavily pretreated patients with advanced epithelial ovarian cancer. Ann Surg Oncol. 2012;19:1326-1333.
21. Chéreau E, Stefanescu D, Selle F, et al. Spontaneous rectovaginal fistula during bevacizumab therapy for ovarian cancer: A case report. Am J Obstet Gynecol. 2009;200:e15-e16.
22. August DA, Serrano D, Poplin E. "Spontaneous" delayed colon and rectal anastomotic complications associated with bevacizumab therapy. J Surg Oncol. 2008;97:180-185.
23. Wolf I, Urban D, Pfeffer R, et al. High incidence of fistula formation during bevacizumab treatment in rectal cancer patients. Acta Oncol. 2007;46:550-553.
24. Adenis A, Vanseymortier L, Foissey D, et al. Bevacizumab and postponed suture leakages after surgery for ulceration cancer. Gut. 2007;56:734.
25. Ley EJ, Vukasin P, Kaiser AM, et al. Delayed rectovaginal fistula: A potential complication of bevacizumab (Avastin). Dis Colon Rectum. 2007;50:930.
26. Koskas M, Chereau E, Ballester M, et al. Wound complications after bevacizumab treatment in patients operated on for ovarian cancer. Anticancer Res. 2010;30:4743-4747.
27. Randall LM, Monk BJ. Bevacizumab toxicities and their management in ovarian cancer. Gynecol Oncol. 2010;117:497-504.